Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 6/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 4/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.46 |
| ▸ | SRC | P12931 | 4/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180336 | 0.90 | MAPK8 (0.50) | WEE1MAPK14ABL1FGFR1SRC | |
| SCHEMBL4181014 | 0.89 | WEE1 (0.51) | WEE1MAPK14LCKABL1FGFR1 | |
| SCHEMBL4173564 | 0.89 | MAPK14 (0.64) | WEE1MAPK14LCKABL1FGFR1 | |
| SCHEMBL4193017 | 0.88 | CCND1 (0.44) | WEE1MAPK14FGFR1TNK2FGFR2 | |
| SCHEMBL13928692 | 0.87 | WEE1 (0.51) | WEE1MAPK14LCKABL1FGFR1 | |
| SCHEMBL4186590 | 0.87 | CCND1 (0.48) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4179272 | 0.85 | MAPK14 (0.48) | WEE1MAPK14LCKABL1FGFR1 | |
| SCHEMBL4186245 | 0.85 | LCK (0.49) | WEE1MAPK14LCKABL1FGFR1 | |
| SCHEMBL4178516 | 0.85 | TNK2 (0.48) | ABL1SRCTNK2 | |
| SCHEMBL4176329 | 0.85 | FGFR1 (0.47) | WEE1MAPK14LCKABL1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | claimed |
| EP-1846403-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-10-24 | — | — | EP | claimed |
| WO-2006082492-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-10 | — | — | WO | claimed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
| EP-1846403-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082492-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | IL1B, TPMT, IL1R1 | WEE1 2618/4885MAPK14 1323/4885LCK 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.